Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Dec;54(12):2978-86.
doi: 10.1007/s00125-011-2325-z. Epub 2011 Oct 13.

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study

E Imai  1 , J C N Chan, S Ito, T Yamasaki, F Kobayashi, M Haneda, H Makino; ORIENT study investigators
Affiliations
Randomized Controlled Trial

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study

E Imai et al. Diabetologia. 2011 Dec.

Abstract

Aims/hypothesis: The renal and cardiovascular protective effects of angiotensin receptor blocker (ARB) remain controversial in type 2 diabetic patients treated with a contemporary regimen including an angiotensin converting enzyme inhibitor (ACEI).

Methods: We examined the effects of olmesartan, an ARB, on primary composite outcome of doubling of serum creatinine, endstage renal disease and death in type 2 diabetic patients with overt nephropathy. Secondary outcome included composite cardiovascular outcomes, changes in renal function and proteinuria. Randomisation and allocation to trial group were carried out by a central computer system. Participants, caregivers, the people carrying out examinations and people assessing the outcomes were blinded to group assignment.

Results: Five hundred and seventy-seven (377 Japanese, 200 Chinese) patients treated with antihypertensive therapy (73.5% [n = 424] received concomitant ACEI), were given either once-daily olmesartan (10-40 mg) (n = 288) or placebo (n = 289) over 3.2 ± 0.6 years (mean±SD). In the olmesartan group, 116 developed the primary outcome (41.1%) compared with 129 (45.4%) in the placebo group (HR 0.97, 95% CI 0.75, 1.24; p = 0.791). Olmesartan significantly decreased blood pressure, proteinuria and rate of change of reciprocal serum creatinine. Cardiovascular death was higher in the olmesartan group than the placebo group (ten vs three cases), whereas major adverse cardiovascular events (cardiovascular death plus non-fatal stroke and myocardial infarction) and all-cause death were similar between the two groups (major adverse cardiovascular events 18 vs 21 cases, all-cause deaths; 19 vs 20 cases). Hyperkalaemia was more frequent in the olmesartan group than the placebo group (9.2% vs 5.3%).

Conclusions/interpretation: Olmesartan was well tolerated but did not improve renal outcome on top of ACEI.

Trial registration: ClinicalTrials.gov NCT00141453.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier analysis of the time to primary composite renal endpoint in type 2 diabetic patients with overt proteinuria and renal insufficiency. Solid line, olmesartan; dashed line, placebo
Fig. 2
Fig. 2
Kaplan–Meier analysis of the time to secondary composite cardiovascular endpoint in type 2 diabetic patients with overt proteinuria and renal insufficiency. Solid line, olmesartan; dashed line, placebo
Fig. 3
Fig. 3
Changes in proteinuria expressed as percentage change of urinary protein/creatinine ratio from baseline during treatment with olmesartan or placebo in type 2 diabetic patients with overt proteinuria and renal insufficiency. Solid line, black circles, olmesartan; dashed line, white circles, placebo. p = 0.005
Fig. 4
Fig. 4
Cumulative frequency distribution of yearly rate of change of 1/SCr. The two arrows refer to the median values in the placebo or olmesartan groups. Black circles, olmesartan; white circles, placebo
See this image and copyright information in PMC

References

    1. Ministry of Health, Labor and Welfare (2009) National Health and Nutrition Survey in 2007. www.mhlw.go.jp/houdou/2008/12/h1225-5.html. Accessed on 24 April 2009
    1. Lam TH, Liu LJ, Janus ED, Lam KSL, Hedley AJ. Fibrinogen, other cardiovascular risk factors and diabetes mellitus in Hong Kong Chinese: a community with high prevalence of type 2 diabetes mellitus and impaired glucose tolerance. Diabetic Med. 2000;17:798–806. doi: 10.1046/j.1464-5491.2000.00384.x. - DOI - PubMed
    1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782–787. doi: 10.1038/414782a. - DOI - PubMed
    1. United States Renal Data System (2009) Excerpts from the United States Renal Data System 2008 Annual Data Report: International comparison. Am J Kidney Dis 53(Suppl 1):S297–S308
    1. Japanese Society of Dialysis Therapy: An overview of regular dialysis treatment in Japan as of Dec 31, 2007. http://docs.jsdt.or.jp/overview/. Accessed 24 April 2009

Publication types

MeSH terms

Associated data